New Directions in the Management of Mantle Cell Lymphoma

 

 

 

 


ACKNOWLEDGEMENT

This activity is supported by an educational grant from Takeda Oncology.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, February 17, 2015 from 1:00 PM EST - 2:00 PM EST
Enduring Material
The enduring material will be available from February 17, 2015 to August 17, 2015.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Outline the histologic types and prognostic models used in the assessment of patients with MCL
Apply evidence-based approaches to the initial treatment of patients with MCL
Implement approaches to the management of patients with relapsed/refractory MCL, with attention to new/emerging therapies

INTENDED AUDIENCE
Hematologic oncologists, pathologists, pharmacists, oncology nurses and other clinicians involved in the diagnosis and management of patients with mantle cell lymphoma are the target audience for this planned activity.

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Julie M. Vose, MD, MBA Research Grant Support: Bristol-Meyers Squibb, Celgene, Genentech, GlaxoSmithKline, Incyte Corporation, Janssen Biotech, Pharmacylics, Spectrum
James O. Armitage, MD Consultant: Celgene, GlaxoSmithKline, Roche, Spectrum, Ziopharm Board of Directors: Tesario Bio, Inc.
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University has no disclosures to report relevant to this activity.
Amit K. Verma, MB,BS Has nothing to disclose relative to this activity
PlatformQ Health, Inc  
Deborah Sharkey, Senior Program Manager Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Personalizing the Management of Advanced Gastric Cancer

 

 

 

ACKNOWLEDGEMENT
This activity is supported by an educational grant from Lilly.

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education.

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.


CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The University of Nebraska Medical Center, Center for Continuing Education designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Monday, March 2, 2015 from 2:00 PM EST - 3:00 PM EST
Enduring Material
The enduring material will be available from March 2, 2015 – September 2, 2015.

ACTIVITY DESCRIPTION
Advanced gastric cancer is an aggressive disease with poor clinical outcomes, especially in advanced disease. Although surgery followed by chemoradiotherapy is the standard protocol for treating early-stage gastric cancer that is resectable, this approach is suitable for 25% of patients with gastric cancer. For patients with advanced gastric cancer, a range of chemotherapy agents and regimens have been investigated in clinical trials in the last 20 years and are commonly used in clinical practice. However, such regimens are often unsuitable for patients with poor performance status, and both geographic and ethnic variations in disease pathogenesis and biology make the application of trial results challenging for clinicians.

Until recently, progress in targeted treatments for gastric cancer has been slower than for other solid tumors, and there have been no options for second-line therapy in the advanced setting. The recent United States Food and Drug Administration approval of a biologic agent for treating advanced gastric cancer, combined with the investigation of several other novel agents that target a range of pathways implicated in gastric cancer pathogenesis heralds a new treatment era for patients with advanced gastric cancer. Accordingly, clinicians will need education about the biology of gastric cancer to support patient selection for appropriate treatment in the advanced setting.


LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Summarize recent scientific research into the molecular pathways involved in the pathogenesis and progression of gastric cancer
Apply new scientific data to implement treatment strategies for managing patients with advanced gastric cancer
Describe the rationale for targeted therapies in the treatment of advanced gastric cancer

INTENDED AUDIENCE
This activity is intended for medical oncologists, gastroenterologists, pathologists, oncology nurses and other clinicians involved in the diagnosis and treatment of patients with gastric cancer.

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to http://www.omedlive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.


HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FINANCIAL DISCLOSURES

Presenters: Financial Disclosures:
Manish A. Shah, MD Research: Sanofi-Aventis
Kelsey Klute, MD Has nothing to disclose.
University of Nebraska Medical Center, Center for Continuing Education  
Lois Colburn, Executive Director Has nothing to disclose
Brenda C. Ram, CMP, CHCP, Coordinator Has nothing to disclose
Chandrakanth Are, MD (Peer Reviewer) Has nothing to disclose
PlatformQ Health, Inc  
Anne Roc, PhD, Medical Director Has nothing to disclose.
Deborah Sharkey, Senior Program Manager Has nothing to disclose.

CONTACT INFORMATION
Accreditation Support
Accreditation Support: Please contact the University of Nebraska Medical Center, Center for Continuing Education at conted@unmc.edu or call 402-559-4152.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Preventing and Treating Inhibitors in Patients with Hemophilia: Strategies for Success

 

 

 

 

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC


ACKNOWLEDGEMENT

This activity is supported by PlatformQ Health Education, LLC.

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION
Live Activity
Friday, March 6, 2015 from 11:00 AM EST - 12:00 PM EST

Enduring Material

The enduring material will be available from March 6, 2015 – September 6, 2015.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Identify risk factors for inhibitor development among patients with hemophilia
Compare the risks and benefits of switching from plasma-derived to recombinant factor VIII replacements with respect to risk for inhibitor development
Apply individualized treatment strategies to the care of patients with low-responding and high-responding inhibitors to improve outcomes for patients with hemophilia


TARGET AUDIENCE

This activity has been designed to meet the educational needs of hematologic oncologists, medical oncologists, and other clinicians involved in the care of patients with hemophilia including nurses, nurse practitioners, physician assistants, particularly those practicing at recognized hemophilia treatment centers (HTCs).

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to http://www.omedlive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Patrick Fogarty, MD
Assistant Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania

Consulting Fees: Amgen, Bayer Healthcare, Baxter Healthcare, Biogen, Chugai, Novo Nordisk, Pfizer

Contracted Research: Baxter, Biogen, CSL Behring, Pfizer

Lindsey A. Greene, MD
Fellow, Pediatric Hematology/Oncology
The Children's Hospital of Philadelphia
Dr. Greene has no relationships to disclose


The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following PlatformQ Health Education, LLC planners Anne Roc, PharmD, Deborah Sharkey, and Karen Greb-Murphy hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION
Accreditation Support:
Please contact the Postgraduate Institute of Medicine at www.pimed.com.

Technical Support:
For any technical issues or issues with your CME Certificate, contact OMedLive at 877-394-1306 or at Support@OMedLive.com

The Evolving Paradigm of Advanced Prostate Cancer Management

 

 

 

 


ACKNOWLEDGEMENT

This activity is supported by educational grants from Astellas and from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ Health Education, LLC. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Thursday, May 7, 2015 from 10:00 AM to 12:00 PM EST
Enduring Material
The enduring material will be available from May 7, 2015 to November 7, 2015.


LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Integrate available hormonal, cytotoxic and immunotherapeutic agents into the management of patients with CRPC
Outline considerations for personalizing treatment and sequencing new therapies in the management of patients with advanced prostate cancer
Outline the potential role for emerging biomarkers in prognostication and prediction when managing patients with advanced prostate cancer
Describe considerations for the use and combining of novel therapeutic agents in the treatment of patients with advanced prostate cancer

INTENDED AUDIENCE
This activity is intended for oncologists, urologists, pathologists, oncology nurses, pharmacists and other clinicians involved in the diagnosis and treatment of patients with advanced prostate cancer.

ESTIMATED TIME TO COMPLETE
The activity consists of two sessions, each of which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Michael R. Harrison, MD Will be posted prior to the live event
Daniel J. George, MD Will be posted prior to the live event
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
TBD Will be posted prior to the live event
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Non-Small Cell Lung Cancer (NSCLC): A Deep Dive into Recent Advances for Personalized Treatment

 

 

 

 


ACKNOWLEDGEMENT

This activity is supported by educational grants from Merck, BMS, Boehringer Ingelheim and Novartis.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ Health Education, LLC. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Internet Activity
Session One: Tuesday, May 19, 2015 from 12:00 PM EST – 1:00 PM EST
Session Two: Date TBD

Enduring Material
The enduring material will be available from May 19, 2015 to November 19, 2015.


LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Apply guideline recommendation for genetic testing when evaluating a patient with advanced NSCLC
Summarize best practices for patient selection and tissue handling during testing for genetic mutations in NSCLC
Summarize current treatment options, their key therapeutic targets, adverse effects and their limitations for treatment of advanced NSCLC
Evaluate safety and efficacy of emerging novel treatment options and their potential impact for improving outcomes for patients with advanced NSCLC

INTENDED AUDIENCE
This activity is intended for medical and surgical oncologists, radiation oncologists, pulmonologists, oncology nurses and other members of the multidisciplinary healthcare team responsible for the diagnosis and management of patients with non-small cell lung cancers.

ESTIMATED TIME TO COMPLETE
The activity consists of two sessions, each of which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Panagiotis Fidias, MD Will be posted prior to the live event
Mark Socinski, MD Will be posted prior to the live event
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Amit K. Verma, MB, BS Has nothing to disclose relevant to this activity.
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose relevant to this activity.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Multiple Myeloma: Improving Treatment and Outcomes for Patients with Relapsed/Refractory Disease

 

 

 

 


ACKNOWLEDGEMENT

This activity is supported by educational grants from Takeda Oncology and Onyx Pharmaceuticals, an Amgen subsidiary.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, June 16, 2015 from 10:00AM to 12:00PM

Enduring Material
The enduring material will be available from June 16, 2015 to December 16, 2015.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Summarize the latest understanding of clonal heterogeneity as it applies to the treatment of relapsed/refractory MM
Develop treatment strategy for relapsed/refractory MM that optimizes use of currently approved treatment options
Summarize new treatment approaches for relapsed/refractory MM
Apply best practices for management of relapsed/refractory MM by integrating emerging agents with currently approved therapies

INTENDED AUDIENCE
Medical oncologists, hematologists, oncology nurses and other clinicians involved in the diagnosis and treatment of multiple myeloma.

ESTIMATED TIME TO COMPLETE
This activity consists of two sessions, each of which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Kenneth Anderson, MD Will be posted prior to live event
Irene Ghobrial, MD Will be posted prior to live event
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University has no disclosures to report relevant to this activity.
Amit K. Verma, MB,BS Has nothing to disclose relative to this activity
PlatformQ Health, Inc  
Randi O’Hara, Senior Program Manager Has nothing to disclose relevant to this activity.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Mantle Cell Lymphoma: Treatment Advances in the Front-line and Relapsed/Refractory Settings

 

 

 

 


ACKNOWLEDGEMENT

This activity is supported by an educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, June 16, 2015 from 12:00 PM EST - 1:00 PM EST
Enduring Material
The enduring material will be available from June 16, 2015 to December 16, 2015.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Diagnose MCL based on histological characteristics and prognostic models in patients with various clinical presentations
Apply evidence-based strategies to the initial treatment of patients with MCL, while considering treatment efficacy and safety and patient characteristics
Design treatment for patients with relapsed/refractory MCL, with attention to new/emerging therapies

INTENDED AUDIENCE
Medical oncologists, hematologists, oncology nurses and other clinicians involved in the diagnosis and treatment of mantle cell lymphoma are the target audience for this planned activity.

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Ann LaCasce, MD Will be posted prior to the live event
TBD Will be posted prior to the live event
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University has no disclosures to report relevant to this activity.
Amit K. Verma, MB,BS Has nothing to disclose relative to this activity
PlatformQ Health, Inc  
Randi O’Hara, Senior Program Manager Has nothing to disclose relevant to this activity.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

 
OmedLive
Watch Connect online with thousands of your peers.
Connect Engage in real-time Q&A with top factuly.
Choose Learn about the latest treatment options.
Connect Earn AMA PRA
Category 1 Credits
™.